Aixtron Shares Slide 30% from Peak as UBS and Goldman Step In Before H1 Earnings

Despite a 30% drop from highs, UBS and Goldman Sachs build stakes in Aixtron; high order backlog contrasts with weak revenue, while valuation remains elevated.

The narrative around Aixtron has grown increasingly divided in recent weeks. While the share price has tumbled nearly 30% from its June high of €62.68, two of Wall Street’s largest institutions have been quietly building sizable positions. UBS declared a 4.00% stake on July 9, 2026, and Goldman Sachs now holds more than 8.6% of the voting rights — a vote of confidence that stands in stark contrast to the selling pressure gripping the broader semiconductor space.

The equity itself has suffered a sharp near-term reversal. On Friday alone, Aixtron shed 2.79% to close at €43.90, bringing the weekly loss to 10.84% and the monthly decline to 17.57%. The 14-day relative strength index sits at 37.9, edging into slightly oversold territory, while the stock trades well below its 50-day moving average of €52.96. It has, however, crept back toward the 100-day average at €43.70. Annualized 30-day volatility stands at 83.70%, underlining the heavy-handed moves that have characterised trading in the name.

The headwinds are not company-specific. Aixtron is caught in a broad sell-off across the semiconductor equipment sector that has also dragged down ASML and Infineon. The mood was further soured by a Bank of America analyst preview that pointed to a significantly higher order intake in the second quarter — yet the mere anticipation of that report triggered another leg lower, a sign of just how tense the market has become before the half-year results on July 30.

The core of the debate lies in a widening gap between orders and revenue. Aixtron’s order intake surged 30% year-on-year to €171.4 million in the first quarter of 2026, pushing the total order backlog to €359.1 million. Yet revenue in the same period collapsed to €59.4 million from €112.5 million a year earlier. Investors are asking whether that bulging backlog can be converted into sales and margins in time to justify the valuation. The optoelectronics segment, particularly laser chips for optical data links in AI data centres, is seen as a structural growth driver that runs deeper than a simple cyclical upturn.

Aixtron enters this test from a position of financial strength. The company carries zero debt and holds a negative net debt position — effectively, a cash surplus. That balance sheet provides ample breathing room to weather the current revenue trough without any refinancing pressure, even if the conversion of the order book takes longer than hoped.

Valuation, however, remains a sticking point. The forward price-to-earnings ratio for 2026 stands at 67.4, roughly 67% above the median of peers such as Veeco, Besi, ASM International, Süss MicroTec, Jenoptik and Camtek. The market is pricing in considerable growth expectations, leaving little room for disappointment. The majority of analysts rate the stock neutral, with a consensus target not far from the current price.

That leaves two camps facing off: deep-pocketed institutional buyers betting on a fundamental payoff, and a market that remains nervous about the pace of execution. The list of institutional names building exposure is not limited to UBS and Goldman Sachs — other Wall Street houses are said to have added to their positions during the decline. Meanwhile, the stock is still up 124.27% year-to-date and 170.90% over the past twelve months, and from its 52-week low of €12.02 it has soared 265.38%.

Everything now points to July 30. When Aixtron publishes its half-year figures, the market will finally see whether the order backlog is translating into hard revenue growth and margin expansion. Until then, the shares are likely to remain caught between technical support levels and the unresolved debate over the company’s ability to convert its record order book into financial results.